NLM Digital Collections

Search

Start Over Subjects Asthma -- drug therapy ✖Remove constraint Subjects: Asthma -- drug therapy Subjects Humans ✖Remove constraint Subjects: Humans

1. Mepolizumab (Nucala??, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Campbell, Jonathan D., author
Chapman, Rick, author
Shore, Karen K., author
Weissberg, Jed, author
Whittington, Melanie, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016
Subject(s):
Adrenergic beta-2 Receptor Agonists -- economics
Adrenergic beta-2 Receptor Agonists -- therapeutic use
Anti-Asthmatic Agents -- administration & dosage
Anti-Asthmatic Agents -- economics
Antibodies, Monoclonal, Humanized -- administration & dosage
Antibodies, Monoclonal, Humanized -- economics
Asthma -- drug therapy
Asthma -- immunology
Eosinophilia -- drug therapy
Interleukin-5 -- immunology
Cost-Benefit Analysis
Glucocorticoids -- administration & dosage
Humans
United States

2. Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2018
Subject(s):
Antibodies, Monoclonal -- therapeutic use
Asthma -- drug therapy
Inflammation -- drug therapy
Antibodies, Monoclonal -- adverse effects
Antibodies, Monoclonal -- economics
Biological Therapy
Cost-Benefit Analysis
Hypersensitivity -- drug therapy
Inflammation -- complications
Treatment Outcome
Humans
United States